InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
3
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-35.6%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Murphy Matthew B., Conseiller Juridique Général. Director active across 1 company, notably Nautilus Biotechnology, Inc.. In total, 4 filings have been logged. Split: 3 buys · 0 sell. Total volume traded: €71k. Activity tracked since 13 August 2021. The latest transaction was disclosed on 12 August 2022 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations4 total
2,500 shares@ US$2.856.7% of flowCommon StockSEC:0001808805-22-000093:0
Ideal exit: 9 May 2023 (T+270)
10,000 shares@ US$3.280.013% mcap32.9% of flowCommon StockSEC:0001808805-22-000056:0
5,000 shares@ US$7.561331.3% of flowCommon StockSEC:0001808805-21-000010
Ideal exit: 10 May 2022 (T+270)
5,000 shares@ US$7.56130.013% mcap33.5% of flowCommon StockSEC:0001808805-21-000010:0
Ideal exit: 10 May 2022 (T+270)
4 of 4 declarations
About Murphy Matthew B.
Matthew B. Murphy is the General Counsel at Nautilus Biotechnology, Inc. In this role, he is responsible for the company's legal affairs and compliance. His expertise in business law is essential for advising management on legal and regulatory matters. He plays a key role in managing legal risks and protecting the company's interests.
